P/B
2,4
Revvity
Revvity is a global life sciences and diagnostics company formed in 2023 following the rebranding of PerkinElmer. The company operates in two segments: life sciences, which provides reagents and instruments for biopharma and academic research, and signals software, and diagnostics, which offers tools in immunodiagnostics and newborn and reproductive health. Revvity’s products and services are sold worldwide, with major markets in the US, Europe, and China.
Revvity is a global life sciences and diagnostics company formed in 2023 following the rebranding of PerkinElmer. The company operates in two segments: life sciences, which provides reagents and instruments for biopharma and academic research, and signals software, and diagnostics, which offers tools in immunodiagnostics and newborn and reproductive health. Revvity’s products and services are sold worldwide, with major markets in the US, Europe, and China.
$17.2B
Market Cap • 10/9/2026
1947
(79 years)
Founded
1972
(54 years ago)
IPO
NYSE
Listing Exchange
United States
Country
S&P500 Participant
Index Composite • 2026
Valuation
P/S
5,9
P/EBITDA
22,2
P/OCF
27,4
P/FCF
30,8
P/E
73,4
BVPS
64,8
EPS
2,1
Market Cap
Market Cap
17,2B
EV
19,5B
EV/Revenue
6,7
EV/EBITDA
25,2
EV/EBIT
54,4
Payout
Dividend Per Share
0,3
Dividend Yield
0,2%
Buyback Yield
2,7%
Total Yield
2,9%
Dividend Yield 5Y
0,3%
Payout
13,4%
Retained Earnings
6,1B
Profitability
Gross Margin
55%
EBITDA Margin
26,6%
EBIT Margin
12,3%
Net Margin
8,2%
D&A/EBITDA
0%
R&D/Revenue
7,4%
Capex/Revenue
2,4%
Capex/D&A
16,7%
Capex/OCF
11,1%
SBC/OCF
3,9%
% PPE
5%
% Goodwill
54,9%
ROE
3,2%
ROIC
3,1%
Growth
CAGR Revenue 5Y
-9,7%
CAGR Op. Income 5Y
-25,5%
CAGR Net Income 5Y
-27,5%
CAGR EPS 5Y
-27,5%
CAGR OCF 5Y
-17,5%
Leverage
N.D./EBITDA
3
Debt/Equity
0%
Current Ratio
1,8
Quick Ratio
1,4
Interest Coverage
—
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!